Following publication, concerns were raised regarding the contribution of the authors of this article. Our investigation, conducted in accordance with Frontiers policies, confirmed a serious breach of our authorship policies and of publication ethics; the article is therefore retracted.
The retraction was approved by the Chief Editors of Oncology and the Chief Executive Editor of Frontiers. The authors do not agree to this retraction.
Summary
Keywords
prostate cancer, androgen deprivation therapy, castration resistant prostate cancer, RISUG adv, Poly ADP ribose polymerase, AR signaling, PI3K
Citation
Frontiers Editorial Office (2023) Retraction: New insights into molecular signalling pathways and current advancements in prostate cancer diagnostics and therapeutics. Front. Oncol. 13:1343833. doi: 10.3389/fonc.2023.1343833
Received
24 November 2023
Accepted
27 November 2023
Published
07 December 2023
Approved by
Luisa Lanfrancone, European Institute of Oncology (IEO), Italy
Volume
13 - 2023
Updates
Copyright
© 2023 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.